SG11202006837XA - Dihydroindolizinone derivative - Google Patents

Dihydroindolizinone derivative

Info

Publication number
SG11202006837XA
SG11202006837XA SG11202006837XA SG11202006837XA SG11202006837XA SG 11202006837X A SG11202006837X A SG 11202006837XA SG 11202006837X A SG11202006837X A SG 11202006837XA SG 11202006837X A SG11202006837X A SG 11202006837XA SG 11202006837X A SG11202006837X A SG 11202006837XA
Authority
SG
Singapore
Prior art keywords
dihydroindolizinone
derivative
dihydroindolizinone derivative
Prior art date
Application number
SG11202006837XA
Other languages
English (en)
Inventor
Toshihiro Kiho
Tatsuya Yano
Satoshi Komoriya
Taisaku Tanaka
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of SG11202006837XA publication Critical patent/SG11202006837XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
SG11202006837XA 2018-01-18 2019-01-18 Dihydroindolizinone derivative SG11202006837XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018006269 2018-01-18
PCT/JP2019/001364 WO2019142883A1 (fr) 2018-01-18 2019-01-18 Dérivé de dihydro-indolizinone

Publications (1)

Publication Number Publication Date
SG11202006837XA true SG11202006837XA (en) 2020-08-28

Family

ID=67302218

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202006837XA SG11202006837XA (en) 2018-01-18 2019-01-18 Dihydroindolizinone derivative

Country Status (12)

Country Link
US (1) US11530211B2 (fr)
EP (1) EP3741757B1 (fr)
JP (1) JP7359697B2 (fr)
KR (1) KR20200110338A (fr)
CN (1) CN111630052B (fr)
AU (1) AU2019208634A1 (fr)
CA (1) CA3088968C (fr)
ES (1) ES2958118T3 (fr)
IL (1) IL276125A (fr)
SG (1) SG11202006837XA (fr)
TW (1) TWI818948B (fr)
WO (1) WO2019142883A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3998107A4 (fr) * 2019-07-08 2023-07-26 Tokyo Institute of Technology Procédé de production d'une cellule productrice d'insuline à l'aide de dérivés de dihydroindolizinone

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039059A1 (es) 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
JP2003128551A (ja) 2001-08-15 2003-05-08 Sankyo Co Ltd 新規抗糖尿病医薬組成物
AU2006279280A1 (en) 2005-08-18 2007-02-22 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating neurological disease
EP1999253B1 (fr) 2006-03-02 2019-05-22 Viacyte, Inc. Cellules précurseurs endocrines, cellules exprimant des hormones pancréatiques et procédés de productions associés
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
WO2010077686A1 (fr) * 2008-12-08 2010-07-08 Sirtris Pharmaceuticals, Inc. Isoindolinone et analogues apparentés comme modulateurs de sirtuine
EP2644694B1 (fr) 2010-10-28 2018-07-11 National University Corporation Kumamoto University Procédé et milieu de culture pour améliorer l'efficacité d'induction de différenciation de cellules souches pluripotentes
WO2012121168A1 (fr) * 2011-03-04 2012-09-13 国立大学法人京都大学 Inhibiteur de kinase
DK2844739T3 (da) 2012-04-30 2019-09-30 Univ Health Network FREMGANGSMÅDER OG SAMMENSÆTNINGER TIL GENERERING AF PANCREATISKE PROGENITORER OG FUNKTIONELLE BETA-CELLER UD FRA hPSC'ER
JP2014161257A (ja) 2013-02-22 2014-09-08 Univ Of Tokyo 多能性幹細胞から膵ランゲルハンス島を製造する方法
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
WO2015020113A1 (fr) 2013-08-07 2015-02-12 国立大学法人京都大学 Méthode de production de cellule productrice d'hormone pancréatique
US20160208215A1 (en) 2013-08-30 2016-07-21 Novo Nordisk A/S Generation of Endocrine Progenitor Cells from Human Pluripotent Stem Cells Using Small Molecules
JP6351018B2 (ja) 2014-02-21 2018-07-04 国立大学法人 熊本大学 アミノ酸組成変更培地を用いた幹細胞の分化誘導方法、及び該培地を含む培地キット
JP6094516B2 (ja) 2014-03-19 2017-03-15 三菱電機株式会社 エレベーター装置
DK3143127T3 (da) 2014-05-16 2021-09-13 Janssen Biotech Inc Anvendelse af små molekyler til at forstærke mafa-ekspression i endokrine pankreasceller
EP3147356B1 (fr) 2014-05-20 2024-03-13 Tokyo Institute of Technology Procédé d'induction de la différenciation des cellules productrices d'insuline
WO2016019228A1 (fr) * 2014-07-31 2016-02-04 Merck Patent Gmbh Dérivés d'indolizine pouvant être employés dans des maladies neurodégénératives
WO2016100921A1 (fr) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Procédés de génération de cellules β dérivées de cellules souches et leurs utilisations
WO2016100925A1 (fr) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Procédés de génération de cellules β dérivées de cellules souches augmentées et leurs utilisations
WO2016100898A1 (fr) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Protocole de différentiation dirigée in vitro sans sérum pour générer des cellules b dérivées de cellules souches et leurs utilisations
CN113234661A (zh) 2014-12-18 2021-08-10 哈佛学院校长同事会 干细胞来源的β细胞的产生方法及其使用方法
US10190096B2 (en) 2014-12-18 2019-01-29 President And Fellows Of Harvard College Methods for generating stem cell-derived β cells and uses thereof
WO2016141460A1 (fr) 2015-03-11 2016-09-15 The University Of British Columbia Thérapies à cellules progénitrices endocriniennes pancréatiques pour le traitement de l'obésité et du diabète de type 2 (dt2)

Also Published As

Publication number Publication date
TW201938156A (zh) 2019-10-01
CA3088968C (fr) 2023-10-17
WO2019142883A1 (fr) 2019-07-25
EP3741757A1 (fr) 2020-11-25
US20210053965A1 (en) 2021-02-25
JPWO2019142883A1 (ja) 2021-01-14
AU2019208634A1 (en) 2020-08-06
CN111630052A (zh) 2020-09-04
EP3741757A4 (fr) 2021-11-03
AU2019208634A2 (en) 2020-09-24
IL276125A (en) 2020-08-31
CA3088968A1 (fr) 2019-07-25
CN111630052B (zh) 2023-04-18
ES2958118T3 (es) 2024-02-01
JP7359697B2 (ja) 2023-10-11
EP3741757B1 (fr) 2023-07-26
US11530211B2 (en) 2022-12-20
TWI818948B (zh) 2023-10-21
KR20200110338A (ko) 2020-09-23

Similar Documents

Publication Publication Date Title
DK3793565T3 (en) Mcl-1-inhibitorer
DK3467457T3 (en) Vibrationssensor
DK3759096T3 (en) Cd73-inhibitorer
CA185383S (en) Casque
PT3810587T (pt) Alcoxipiridinilindolsulfonamidas substituídas
CA185384S (en) Casque
CA185382S (en) Casque
CA185385S (en) Casque
DK3773537T3 (en) Stat3-hæmmere
DK3554057T3 (en) Audioheadsetsystem
DK3768830T3 (en) Cancerterapi
IL283990A (en) Modified oxopyridine derivatives
DK3613739T3 (en) Integrin-antagonister
DK3753395T3 (en) Indvendigt luftstyringssystem
CA184989S (en) Uroflowmeter
DK3633783T3 (en) Universal-powerbank
IL279938A (en) History of spirochroman
CA184992S (en) Uroflowmeter
IL290964A (en) A 2-aminoquinazolinone derivative
LT3796975T (lt) Sulfonilaminobenzamido dariniai
EP3841303C0 (fr) Microsoufflante
DK3768906T3 (en) Træmodul
DK3650069T3 (en) Trakeostomiventil
SG11202007979UA (en) Dihydrochromene derivative
SG11202006837XA (en) Dihydroindolizinone derivative